BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Hydrocodone | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Magnesium sulfate | The therapeutic efficacy of BL-1020 can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Mirtazapine | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Orphenadrine | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Pramipexole | BL-1020 may increase the sedative activities of Pramipexole. |
| Ropinirole | BL-1020 may increase the sedative activities of Ropinirole. |
| Rotigotine | BL-1020 may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with BL-1020. |
| Sodium oxybate | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Thalidomide | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | BL-1020 may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when BL-1020 is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when BL-1020 is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with BL-1020. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with BL-1020. |
| Sulpiride | BL-1020 may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with BL-1020. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of BL-1020. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of BL-1020. |
| Mequitazine | BL-1020 may increase the arrhythmogenic activities of Mequitazine. |
| Tetrabenazine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Deutetrabenazine. |
| Thiopental | The risk or severity of adverse effects can be increased when BL-1020 is combined with Thiopental. |
| Metyrosine | The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with BL-1020. |
| Ethanol | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of BL-1020. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when BL-1020 is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when BL-1020 is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when BL-1020 is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when BL-1020 is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when BL-1020 is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with BL-1020. |
| Indalpine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when BL-1020 is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when BL-1020 is combined with Alaproclate. |
| Esmolol | The serum concentration of Esmolol can be increased when it is combined with BL-1020. |
| Betaxolol | The serum concentration of Betaxolol can be increased when it is combined with BL-1020. |
| Metoprolol | The serum concentration of Metoprolol can be increased when it is combined with BL-1020. |
| Atenolol | The serum concentration of Atenolol can be increased when it is combined with BL-1020. |
| Timolol | The serum concentration of Timolol can be increased when it is combined with BL-1020. |
| Sotalol | The serum concentration of Sotalol can be increased when it is combined with BL-1020. |
| Propranolol | The serum concentration of Propranolol can be increased when it is combined with BL-1020. |
| Labetalol | The serum concentration of Labetalol can be increased when it is combined with BL-1020. |
| Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with BL-1020. |
| Alprenolol | The serum concentration of Alprenolol can be increased when it is combined with BL-1020. |
| Pindolol | The serum concentration of Pindolol can be increased when it is combined with BL-1020. |
| Carvedilol | The serum concentration of Carvedilol can be increased when it is combined with BL-1020. |
| Propafenone | The serum concentration of Propafenone can be increased when it is combined with BL-1020. |
| Acebutolol | The serum concentration of Acebutolol can be increased when it is combined with BL-1020. |
| Nadolol | The serum concentration of Nadolol can be increased when it is combined with BL-1020. |
| Bevantolol | The serum concentration of Bevantolol can be increased when it is combined with BL-1020. |
| Practolol | The serum concentration of Practolol can be increased when it is combined with BL-1020. |
| Penbutolol | The serum concentration of Penbutolol can be increased when it is combined with BL-1020. |
| Oxprenolol | The serum concentration of Oxprenolol can be increased when it is combined with BL-1020. |
| Dexpropranolol | The serum concentration of Dexpropranolol can be increased when it is combined with BL-1020. |
| Celiprolol | The serum concentration of Celiprolol can be increased when it is combined with BL-1020. |
| Nebivolol | The serum concentration of Nebivolol can be increased when it is combined with BL-1020. |
| Bufuralol | The serum concentration of Bufuralol can be increased when it is combined with BL-1020. |
| Bopindolol | The serum concentration of Bopindolol can be increased when it is combined with BL-1020. |
| Bupranolol | The serum concentration of Bupranolol can be increased when it is combined with BL-1020. |
| Indenolol | The serum concentration of Indenolol can be increased when it is combined with BL-1020. |
| Arotinolol | The serum concentration of Arotinolol can be increased when it is combined with BL-1020. |
| Levobetaxolol | The serum concentration of Levobetaxolol can be increased when it is combined with BL-1020. |
| Talinolol | The serum concentration of Talinolol can be increased when it is combined with BL-1020. |
| Anisodamine | The serum concentration of Anisodamine can be increased when it is combined with BL-1020. |
| Bucindolol | The serum concentration of Bucindolol can be increased when it is combined with BL-1020. |
| Esatenolol | The serum concentration of Esatenolol can be increased when it is combined with BL-1020. |
| Cloranolol | The serum concentration of Cloranolol can be increased when it is combined with BL-1020. |
| Mepindolol | The serum concentration of Mepindolol can be increased when it is combined with BL-1020. |
| Epanolol | The serum concentration of Epanolol can be increased when it is combined with BL-1020. |
| Tertatolol | The serum concentration of Tertatolol can be increased when it is combined with BL-1020. |
| Landiolol | The serum concentration of Landiolol can be increased when it is combined with BL-1020. |
| Morphine | The risk or severity of hypotension and CNS depression can be increased when BL-1020 is combined with Morphine. |
| Codeine | The risk or severity of hypotension and CNS depression can be increased when BL-1020 is combined with Codeine. |
| Hydromorphone | The risk or severity of hypotension and CNS depression can be increased when BL-1020 is combined with Hydromorphone. |
| Meperidine | The risk or severity of hypotension and CNS depression can be increased when BL-1020 is combined with Meperidine. |
| Oxycodone | The risk or severity of hypotension and CNS depression can be increased when BL-1020 is combined with Oxycodone. |